TY - JOUR
T1 - Small molecule inhibits KCNQ channels with a non-blocking mechanism
AU - Li, Junnan
AU - Yang, Zhenni
AU - Zhang, Shaoying
AU - Ye, Yangliang
AU - He, Jiangnan
AU - Zhang, Yan
AU - Han, Huayun
AU - Kong, Wan
AU - Liu, Jiangru
AU - Min, Yu
AU - Shen, Juwen
AU - Mei, Lianghe
AU - Chen, Zongsheng
AU - Hou, Panpan
AU - Guo, Jiangtao
AU - Zhang, Qiansen
AU - Yang, Huaiyu
N1 - Publisher Copyright:
© The Author(s), under exclusive licence to Springer Nature America, Inc. 2025.
PY - 2025/7
Y1 - 2025/7
N2 - Voltage-gated ion channels (VGICs) are crucial targets for neuropsychiatric therapeutics owing to their role in controlling neuronal excitability and the established link between their dysfunction and neurological diseases, highlighting the importance of identifying modulators with distinct mechanisms. Here we report two small-molecule modulators with the same chemical scaffold, Ebio2 and Ebio3, targeting a potassium channel KCNQ2, with opposite effects: Ebio2 acts as a potent activator, whereas Ebio3 serves as a potent and selective inhibitor. Guided by cryogenic electron microscopy, patch-clamp recordings and molecular dynamics simulations, we reveal that Ebio3 attaches to the outside of the inner gate, employing a unique non-blocking inhibitory mechanism that directly squeezes the S6 pore helix to inactivate the KCNQ2 channel. Ebio3 also showed efficacy in inhibiting currents of KCNQ2 pathogenic gain-of-function mutations, presenting an avenue for VGIC-targeted therapies. Overall, these findings contribute to the understanding of KCNQ2 inhibition and provide insights into developing selective, non-blocking VGIC inhibitors. (Figure presented.)
AB - Voltage-gated ion channels (VGICs) are crucial targets for neuropsychiatric therapeutics owing to their role in controlling neuronal excitability and the established link between their dysfunction and neurological diseases, highlighting the importance of identifying modulators with distinct mechanisms. Here we report two small-molecule modulators with the same chemical scaffold, Ebio2 and Ebio3, targeting a potassium channel KCNQ2, with opposite effects: Ebio2 acts as a potent activator, whereas Ebio3 serves as a potent and selective inhibitor. Guided by cryogenic electron microscopy, patch-clamp recordings and molecular dynamics simulations, we reveal that Ebio3 attaches to the outside of the inner gate, employing a unique non-blocking inhibitory mechanism that directly squeezes the S6 pore helix to inactivate the KCNQ2 channel. Ebio3 also showed efficacy in inhibiting currents of KCNQ2 pathogenic gain-of-function mutations, presenting an avenue for VGIC-targeted therapies. Overall, these findings contribute to the understanding of KCNQ2 inhibition and provide insights into developing selective, non-blocking VGIC inhibitors. (Figure presented.)
UR - https://www.scopus.com/pages/publications/85217179037
U2 - 10.1038/s41589-024-01834-8
DO - 10.1038/s41589-024-01834-8
M3 - 文章
C2 - 39814994
AN - SCOPUS:85217179037
SN - 1552-4450
VL - 21
SP - 1100
EP - 1109
JO - Nature Chemical Biology
JF - Nature Chemical Biology
IS - 7
ER -